First-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Dual Immunotherapy Combined With Chemotherapy

NCT07400315 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Iparomlimab and Tuvonralimab Injection in combination with TFOX

Sponsor

The First Affiliated Hospital with Nanjing Medical University